| Title |
Diacerein for osteoarthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, February 2014
|
| DOI | 10.1002/14651858.cd005117.pub3 |
| Pubmed ID | |
| Authors |
Tania S.A. Fidelix, Cristiane R Macedo, Lara J Maxwell, Virginia Fernandes Moça Trevisani |
| Abstract |
Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. There is currently no consensus on what is the best treatment to improve OA symptoms and slow disease progression. Diacerein is an anthraquinone synthesised in 1980 that interferes with interleukin-1, an inflammatory mediator. It has been proposed that diacerein acts as a slow-acting, symptom-modifying and perhaps disease-structure-modifying drug for OA. This is an update of a Cochrane review first published in 2006. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 10 | 50% |
| Colombia | 2 | 10% |
| Nigeria | 1 | 5% |
| United Kingdom | 1 | 5% |
| Unknown | 6 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 90% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 323 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Netherlands | 1 | <1% |
| Romania | 1 | <1% |
| Unknown | 320 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 49 | 15% |
| Researcher | 38 | 12% |
| Student > Ph. D. Student | 36 | 11% |
| Student > Bachelor | 35 | 11% |
| Student > Doctoral Student | 18 | 6% |
| Other | 52 | 16% |
| Unknown | 95 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 106 | 33% |
| Nursing and Health Professions | 30 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 6% |
| Agricultural and Biological Sciences | 10 | 3% |
| Psychology | 9 | 3% |
| Other | 42 | 13% |
| Unknown | 107 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2019.
All research outputs
#2,274,914
of 25,728,855 outputs
Outputs from Cochrane database of systematic reviews
#4,672
of 13,136 outputs
Outputs of similar age
#26,212
of 329,633 outputs
Outputs of similar age from Cochrane database of systematic reviews
#87
of 225 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,136 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,633 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.